Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $118.28 and traded as high as $133.68. UCB shares last traded at $133.68, with a volume of 270 shares.
UCB Stock Up 5.2 %
The stock has a fifty day simple moving average of $118.28 and a two-hundred day simple moving average of $94.52.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
- Five stocks we like better than UCB
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- MarketBeat Week in Review – 4/22 – 4/26
- 3 Healthcare Dividend Stocks to Buy
- 3 Stocks Leading the U.S. Agriculture Comeback
- The Significance of Brokerage Rankings in Stock Selection
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
